CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF83 (ImmuneEditome ID:55769)

1. Gene summary of enriched editing regions for ZNF83

check button Gene summary
Gene informationGene symbol

ZNF83

Gene ID

55769

GeneSynonymsHPF1|ZNF816B
GeneCytomap

19q13.41

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 83|zinc finger protein 816B|zinc finger protein HPF1
GeneModificationdate20230329
UniprotIDL0R8M2;P51522;A0A024R4L3;M0R0P3;M0R3A5;M0R1T0;M0R099
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:52603667-52613324:-ENST00000301096.6ENSG00000167766.17ZNF83exonicLTR9A1,MER4A,(TTAT)n,MER65C,AluY,AluSp,AluSx1,(T)n,AluSc,MER83,(AT)n,AluJb,AluSx3,AluSx,AluSz,MER21B,AluSg,AluSc5,L1MA3chr19:52603667-52613324:-.alignment
chr19:52603667-52613324:-ENST00000536937.4ENSG00000167766.17ZNF83exonicLTR9A1,MER4A,(TTAT)n,MER65C,AluY,AluSp,AluSx1,(T)n,AluSc,MER83,(AT)n,AluJb,AluSx3,AluSx,AluSz,MER21B,AluSg,AluSc5,L1MA3chr19:52603667-52613324:-.alignment
chr19:52603667-52613324:-ENST00000541777.5ENSG00000167766.17ZNF83exonicLTR9A1,MER4A,(TTAT)n,MER65C,AluY,AluSp,AluSx1,(T)n,AluSc,MER83,(AT)n,AluJb,AluSx3,AluSx,AluSz,MER21B,AluSg,AluSc5,L1MA3chr19:52603667-52613324:-.alignment
chr19:52603667-52613324:-ENST00000545872.1ENSG00000167766.17ZNF83exonicLTR9A1,MER4A,(TTAT)n,MER65C,AluY,AluSp,AluSx1,(T)n,AluSc,MER83,(AT)n,AluJb,AluSx3,AluSx,AluSz,MER21B,AluSg,AluSc5,L1MA3chr19:52603667-52613324:-.alignment
chr19:52603667-52613324:-ENST00000597597.1ENSG00000167766.17ZNF83exonicLTR9A1,MER4A,(TTAT)n,MER65C,AluY,AluSp,AluSx1,(T)n,AluSc,MER83,(AT)n,AluJb,AluSx3,AluSx,AluSz,MER21B,AluSg,AluSc5,L1MA3chr19:52603667-52613324:-.alignment
chr19:52616712-52618719:-ENST00000596930.4ENSG00000167766.17ZNF83exonicAluSx,L1PA8,AluSz,AluY,AluSpchr19:52616712-52618719:-.alignment
chr19:52616712-52618719:-ENST00000597161.4ENSG00000167766.17ZNF83exonicAluSx,L1PA8,AluSz,AluY,AluSpchr19:52616712-52618719:-.alignment
chr19:52616712-52618719:-ENST00000601140.1ENSG00000167766.17ZNF83exonicAluSx,L1PA8,AluSz,AluY,AluSpchr19:52616712-52618719:-.alignment
chr19:52635479-52636980:-ENST00000595171.4ENSG00000167766.17ZNF83ncRNA_intronicAluSq,AluSx,AluJbchr19:52635479-52636980:-.alignment
chr19:52635479-52636980:-ENST00000596440.4ENSG00000167766.17ZNF83ncRNA_intronicAluSq,AluSx,AluJbchr19:52635479-52636980:-.alignment
chr19:52635479-52636980:-ENST00000601237.4ENSG00000167766.17ZNF83ncRNA_intronicAluSq,AluSx,AluJbchr19:52635479-52636980:-.alignment
chr19:52635479-52636980:-ENST00000602232.4ENSG00000167766.17ZNF83ncRNA_intronicAluSq,AluSx,AluJbchr19:52635479-52636980:-.alignment
chr19:52639153-52639740:-ENST00000595171.4ENSG00000167766.17ZNF83ncRNA_intronicAluSp,AluSqchr19:52639153-52639740:-.alignment
chr19:52639153-52639740:-ENST00000596440.4ENSG00000167766.17ZNF83ncRNA_intronicAluSp,AluSqchr19:52639153-52639740:-.alignment
chr19:52639153-52639740:-ENST00000602232.4ENSG00000167766.17ZNF83ncRNA_intronicAluSp,AluSqchr19:52639153-52639740:-.alignment
chr19:52641569-52647604:-ENST00000595171.4ENSG00000167766.17ZNF83ncRNA_intronicAluJo,AluSx,(TTAA)n,AluJb,L2,AluSz,AluSq2,AluSc8,MER4A,LTR61,AluSpchr19:52641569-52647604:-.alignment
chr19:52641569-52647604:-ENST00000596440.4ENSG00000167766.17ZNF83ncRNA_intronicAluJo,AluSx,(TTAA)n,AluJb,L2,AluSz,AluSq2,AluSc8,MER4A,LTR61,AluSpchr19:52641569-52647604:-.alignment
chr19:52641569-52647604:-ENST00000602232.4ENSG00000167766.17ZNF83ncRNA_intronicAluJo,AluSx,(TTAA)n,AluJb,L2,AluSz,AluSq2,AluSc8,MER4A,LTR61,AluSpchr19:52641569-52647604:-.alignment
chr19:52671660-52672086:-ENST00000595171.4ENSG00000167766.17ZNF83ncRNA_intronicAluJr,AluSxchr19:52671660-52672086:-.alignment
chr19:52671660-52672086:-ENST00000596440.4ENSG00000167766.17ZNF83ncRNA_intronicAluJr,AluSxchr19:52671660-52672086:-.alignment
chr19:52671660-52672086:-ENST00000598190.1ENSG00000167766.17ZNF83ncRNA_intronicAluJr,AluSxchr19:52671660-52672086:-.alignment
chr19:52671660-52672086:-ENST00000600457.4ENSG00000167766.17ZNF83ncRNA_intronicAluJr,AluSxchr19:52671660-52672086:-.alignment
chr19:52671660-52672086:-ENST00000602232.4ENSG00000167766.17ZNF83ncRNA_intronicAluJr,AluSxchr19:52671660-52672086:-.alignment
chr19:52688233-52688482:-ENST00000595171.4ENSG00000167766.17ZNF83ncRNA_intronicAluJbchr19:52688233-52688482:-.alignment
chr19:52688233-52688482:-ENST00000596440.4ENSG00000167766.17ZNF83ncRNA_intronicAluJbchr19:52688233-52688482:-.alignment
chr19:52688233-52688482:-ENST00000598190.1ENSG00000167766.17ZNF83ncRNA_intronicAluJbchr19:52688233-52688482:-.alignment
chr19:52688233-52688482:-ENST00000600457.4ENSG00000167766.17ZNF83ncRNA_intronicAluJbchr19:52688233-52688482:-.alignment
chr19:52688233-52688482:-ENST00000602232.4ENSG00000167766.17ZNF83ncRNA_intronicAluJbchr19:52688233-52688482:-.alignment


Top

2. Tumor-specific enriched editing regions for ZNF83


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000167766.17,ZNF83BRCAEAG2.9977e-02image
chr19:52616712-52618719:-KIRCEER2.8605e-02image
ENSG00000167766.17,ZNF83KIRCEAG3.6528e-02image
chr19:52616712-52618719:-LUSCEER1.9643e-03image
ENSG00000167766.17,ZNF83LUSCEAG2.3753e-03image
chr19:52616712-52618719:-THCAEER6.3119e-03image
ENSG00000167766.17,ZNF83THCAEAG1.6730e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:52616712-52618719:-ACCPathEER3.3989e-023.9766e-020.2708image
chr19:52616712-52618719:-KIRPCliEER1.6505e-032.8638e-040.2857image
chr19:52639153-52639740:-KIRPCliEER2.1886e-034.8663e-020.2270image
chr19:52641569-52647604:-KIRPPathEER9.6221e-031.0765e-030.2313image
ENSG00000167766.17,ZNF83KIRPCliEAG4.2562e-034.1304e-040.2612image
chr19:52641569-52647604:-TGCTPathEER3.1566e-023.3525e-020.2351image
ENSG00000167766.17,ZNF83TGCTPathEAG2.8863e-022.6326e-020.2453image
chr19:52603667-52613324:-UCECCliEER3.4172e-022.6369e-020.4269image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:52639153-52639740:-BLCAEER7.9995e-033.0406e-031.3682e+02image
chr19:52616712-52618719:-KICHEER3.8924e-034.5357e-021.5620e-08image
ENSG00000167766.17,ZNF83KICHEAG1.8274e-032.8430e-022.3030e-10image
chr19:52616712-52618719:-KIRPEER4.0843e-024.5396e-025.1074e+01image
chr19:52639153-52639740:-SARCEER2.6756e-033.2464e-024.3119e+03image

Top

3. Enriched editing regions and immune related genes for ZNF83


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:52616712-52618719:-GBMEERENSG00000244932,RP11-529F4.1-0.44308.3323e-057.5634e-08-0.4384imageNNNAMonocytesGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000167615,LENG8-0.42611.8045e-047.0461e-08-0.4393imageNCNBP;CPSF6;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PRPF8;PUM2;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184LENG8T_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
chr19:52616712-52618719:-GBMEERENSG00000240053,LY6G5B-0.42701.8323e-041.2829e-07-0.4313imageNCPSF6;CSTF2T;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28B;LSM11;NOP56;NOP58;PRPF8;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184LY6G5BT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000281896,RP11-274B21.13-0.42652.0240e-041.1660e-06-0.4000imageNNNAMonocytesGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr19:52616712-52618719:-GBMEERENSG00000258682,CTD-2002H8.2-0.42542.0882e-046.2910e-07-0.4091imageNCSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28;LIN28B;MOV10;NOP56;NOP58;PRPF8;SND1;SRSF1;TAF15;TRA2A;U2AF2;UPF1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000254428,RP11-110I1.11-0.41912.7735e-042.1384e-07-0.4244imageNIGF2BP2NAT_cells_follicular_helperGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52616712-52618719:-GBMEERENSG00000243302,RP11-274B21.2-0.41313.5128e-042.8477e-07-0.4204imageNNNAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000182983,ZNF662-0.40934.1442e-046.7246e-07-0.4082imageNCSTF2T;ELAVL1;ELAVL3;FBL;FXR1;HNRNPA1;LIN28B;SAFB2;SRSF1;TAF15;U2AF2;XRN2NAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52616712-52618719:-GBMEERENSG00000239763,AC009120.3-0.40265.0811e-044.3466e-07-0.4144imageNNNAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000230715,RP11-274B21.4-0.40175.3812e-046.7950e-07-0.4080imageNNNAT_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
chr19:52616712-52618719:-GBMEERENSG00000244932,RP11-529F4.1-0.44308.3323e-057.5634e-08-0.4384imageNNNAMonocytesGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000167615,LENG8-0.42611.8045e-047.0461e-08-0.4393imageNCNBP;CPSF6;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PRPF8;PUM2;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184LENG8T_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
chr19:52616712-52618719:-GBMEERENSG00000240053,LY6G5B-0.42701.8323e-041.2829e-07-0.4313imageNCPSF6;CSTF2T;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28B;LSM11;NOP56;NOP58;PRPF8;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184LY6G5BT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000281896,RP11-274B21.13-0.42652.0240e-041.1660e-06-0.4000imageNNNAMonocytesGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr19:52616712-52618719:-GBMEERENSG00000258682,CTD-2002H8.2-0.42542.0882e-046.2910e-07-0.4091imageNCSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28;LIN28B;MOV10;NOP56;NOP58;PRPF8;SND1;SRSF1;TAF15;TRA2A;U2AF2;UPF1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000254428,RP11-110I1.11-0.41912.7735e-042.1384e-07-0.4244imageNIGF2BP2NAT_cells_follicular_helperGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52616712-52618719:-GBMEERENSG00000243302,RP11-274B21.2-0.41313.5128e-042.8477e-07-0.4204imageNNNAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000182983,ZNF662-0.40934.1442e-046.7246e-07-0.4082imageNCSTF2T;ELAVL1;ELAVL3;FBL;FXR1;HNRNPA1;LIN28B;SAFB2;SRSF1;TAF15;U2AF2;XRN2NAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52616712-52618719:-GBMEERENSG00000239763,AC009120.3-0.40265.0811e-044.3466e-07-0.4144imageNNNAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000230715,RP11-274B21.4-0.40175.3812e-046.7950e-07-0.4080imageNNNAT_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
chr19:52616712-52618719:-GBMEERENSG00000244932,RP11-529F4.1-0.44308.3323e-057.5634e-08-0.4384imageNNNAMonocytesGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000167615,LENG8-0.42611.8045e-047.0461e-08-0.4393imageNCNBP;CPSF6;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PRPF8;PUM2;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184LENG8T_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
chr19:52616712-52618719:-GBMEERENSG00000240053,LY6G5B-0.42701.8323e-041.2829e-07-0.4313imageNCPSF6;CSTF2T;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28B;LSM11;NOP56;NOP58;PRPF8;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184LY6G5BT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000281896,RP11-274B21.13-0.42652.0240e-041.1660e-06-0.4000imageNNNAMonocytesGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr19:52616712-52618719:-GBMEERENSG00000258682,CTD-2002H8.2-0.42542.0882e-046.2910e-07-0.4091imageNCSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28;LIN28B;MOV10;NOP56;NOP58;PRPF8;SND1;SRSF1;TAF15;TRA2A;U2AF2;UPF1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000254428,RP11-110I1.11-0.41912.7735e-042.1384e-07-0.4244imageNIGF2BP2NAT_cells_follicular_helperGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52616712-52618719:-GBMEERENSG00000243302,RP11-274B21.2-0.41313.5128e-042.8477e-07-0.4204imageNNNAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000182983,ZNF662-0.40934.1442e-046.7246e-07-0.4082imageNCSTF2T;ELAVL1;ELAVL3;FBL;FXR1;HNRNPA1;LIN28B;SAFB2;SRSF1;TAF15;U2AF2;XRN2NAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52616712-52618719:-GBMEERENSG00000239763,AC009120.3-0.40265.0811e-044.3466e-07-0.4144imageNNNAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-GBMEERENSG00000230715,RP11-274B21.4-0.40175.3812e-046.7950e-07-0.4080imageNNNAT_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
chr19:52641569-52647604:-STADEERENSG00000167766,ZNF83-0.42831.1223e-105.4978e-13-0.4024imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBM10;SAFB2;SLTM;SRSF1;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;KHDRBS1;MOV10;TROVE2NAT_cells_gamma_deltaGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52641569-52647604:-TGCTEERENSG00000116514,RNF19B-0.52309.1709e-094.0670e-09-0.4531imageNEIF4A3;ELAVL1;NONO;TARDBP;U2AF2;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;FTO;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr19:52641569-52647604:-TGCTEERENSG00000104915,STX100.53291.1693e-083.0446e-110.5042imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;KHDRBS1;MOV10;TROVE2NAB_cells_naiveGSVA_HALLMARK_G2M_CHECKPOINT
chr19:52641569-52647604:-TGCTEERENSG00000100994,PYGB-0.52621.2352e-089.6708e-09-0.4432imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr19:52641569-52647604:-TGCTEERENSG00000167733,HSD11B1L0.52392.1116e-081.6139e-090.4634imageNEIF4A3;ELAVL1;NONO;TARDBP;U2AF2;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP2;NOP56;NOP58;PRPF8;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;TAF15;TNRC6A;UPF1;XRN2;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr19:52641569-52647604:-TGCTEERENSG00000167553,TUBA1C-0.49221.5139e-077.7762e-08-0.4177imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;FTO;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr19:52641569-52647604:-TGCTEERENSG00000033050,ABCF2-0.48862.3031e-071.7330e-08-0.4362imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr19:52641569-52647604:-TGCTEERENSG00000183439,TRIM61-0.47365.1418e-077.8499e-09-0.4456imageNELAVL1;TARDBP;U2AF2;CSTF2T;FUS;HNRNPA1;IGF2BP2;NOP58;TAF15;UPF1TRIM61T_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr19:52641569-52647604:-TGCTEERENSG00000146416,AIG10.46211.2387e-063.8225e-080.4266imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TRA2A;U2AF1;UPF1;FTO;KHDRBS1;MOV10;TROVE2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr19:52641569-52647604:-TGCTEERENSG00000120942,UBIAD1-0.46171.2477e-067.3719e-09-0.4463imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;FTO;KHDRBS1;MOV10;TROVE2NAB_cells_naiveGSVA_HALLMARK_SPERMATOGENESIS
chr19:52641569-52647604:-STADEERENSG00000167766,ZNF83-0.42831.1223e-105.4978e-13-0.4024imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBM10;SAFB2;SLTM;SRSF1;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;KHDRBS1;MOV10;TROVE2NAT_cells_gamma_deltaGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52641569-52647604:-TGCTEERENSG00000116514,RNF19B-0.52309.1709e-094.0670e-09-0.4531imageNEIF4A3;ELAVL1;NONO;TARDBP;U2AF2;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;FTO;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr19:52641569-52647604:-TGCTEERENSG00000104915,STX100.53291.1693e-083.0446e-110.5042imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;KHDRBS1;MOV10;TROVE2NAB_cells_naiveGSVA_HALLMARK_G2M_CHECKPOINT
chr19:52641569-52647604:-TGCTEERENSG00000100994,PYGB-0.52621.2352e-089.6708e-09-0.4432imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr19:52641569-52647604:-TGCTEERENSG00000167733,HSD11B1L0.52392.1116e-081.6139e-090.4634imageNEIF4A3;ELAVL1;NONO;TARDBP;U2AF2;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP2;NOP56;NOP58;PRPF8;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;TAF15;TNRC6A;UPF1;XRN2;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr19:52641569-52647604:-TGCTEERENSG00000167553,TUBA1C-0.49221.5139e-077.7762e-08-0.4177imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;FTO;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr19:52641569-52647604:-TGCTEERENSG00000033050,ABCF2-0.48862.3031e-071.7330e-08-0.4362imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr19:52641569-52647604:-TGCTEERENSG00000183439,TRIM61-0.47365.1418e-077.8499e-09-0.4456imageNELAVL1;TARDBP;U2AF2;CSTF2T;FUS;HNRNPA1;IGF2BP2;NOP58;TAF15;UPF1TRIM61T_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr19:52641569-52647604:-TGCTEERENSG00000146416,AIG10.46211.2387e-063.8225e-080.4266imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TRA2A;U2AF1;UPF1;FTO;KHDRBS1;MOV10;TROVE2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr19:52641569-52647604:-TGCTEERENSG00000120942,UBIAD1-0.46171.2477e-067.3719e-09-0.4463imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;FTO;KHDRBS1;MOV10;TROVE2NAB_cells_naiveGSVA_HALLMARK_SPERMATOGENESIS
chr19:52641569-52647604:-STADEERENSG00000167766,ZNF83-0.42831.1223e-105.4978e-13-0.4024imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBM10;SAFB2;SLTM;SRSF1;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;KHDRBS1;MOV10;TROVE2NAT_cells_gamma_deltaGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:52641569-52647604:-TGCTEERENSG00000116514,RNF19B-0.52309.1709e-094.0670e-09-0.4531imageNEIF4A3;ELAVL1;NONO;TARDBP;U2AF2;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;FTO;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr19:52641569-52647604:-TGCTEERENSG00000104915,STX100.53291.1693e-083.0446e-110.5042imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;KHDRBS1;MOV10;TROVE2NAB_cells_naiveGSVA_HALLMARK_G2M_CHECKPOINT
chr19:52641569-52647604:-TGCTEERENSG00000100994,PYGB-0.52621.2352e-089.6708e-09-0.4432imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr19:52641569-52647604:-TGCTEERENSG00000167733,HSD11B1L0.52392.1116e-081.6139e-090.4634imageNEIF4A3;ELAVL1;NONO;TARDBP;U2AF2;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP2;NOP56;NOP58;PRPF8;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;TAF15;TNRC6A;UPF1;XRN2;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr19:52641569-52647604:-TGCTEERENSG00000167553,TUBA1C-0.49221.5139e-077.7762e-08-0.4177imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;FTO;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr19:52641569-52647604:-TGCTEERENSG00000033050,ABCF2-0.48862.3031e-071.7330e-08-0.4362imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;KHDRBS1;MOV10;TROVE2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr19:52641569-52647604:-TGCTEERENSG00000183439,TRIM61-0.47365.1418e-077.8499e-09-0.4456imageNELAVL1;TARDBP;U2AF2;CSTF2T;FUS;HNRNPA1;IGF2BP2;NOP58;TAF15;UPF1TRIM61T_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr19:52641569-52647604:-TGCTEERENSG00000146416,AIG10.46211.2387e-063.8225e-080.4266imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TRA2A;U2AF1;UPF1;FTO;KHDRBS1;MOV10;TROVE2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr19:52641569-52647604:-TGCTEERENSG00000120942,UBIAD1-0.46171.2477e-067.3719e-09-0.4463imageNEIF4A3;ELAVL1;KHSRP;NONO;TARDBP;U2AF2;BCCIP;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;EIF4G2;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPU;IGF2BP1;IGF2BP2;LIN28B;LSM11;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBM10;SAFB2;SLTM;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;U2AF1;UPF1;XRN2;YTHDC1;FTO;KHDRBS1;MOV10;TROVE2NAB_cells_naiveGSVA_HALLMARK_SPERMATOGENESIS

More results



Top

4. Enriched editing regions and immune related splicing for ZNF83


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000167766.17,ZNF83
ESCAEAGIRENSG00000149743.9chr1164225785:64225869:64226097:64226297-0.32407.2079e-031.0049e-07-0.4896imageNBCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28B;LSM11;MSI2;NOP58;NPM1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAGNAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr19:52616712-52618719:-
GBMEERIRENSG00000109083.9chr1728328886:28329276:28330110:28330228-0.37629.1044e-045.4157e-07-0.4437imageNCPSF6;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LIN28;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PRPF8;PUM2;RBM27;SAFB2;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;ZNF184IFT20NK_cells_restingGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-
GBMEERIRENSG00000082014.12chr7151240111:151240522:151241491:151241653-0.39284.2044e-031.1278e-06-0.4005imageNCNBP;CSTF2T;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;IGF2BP2;IGF2BP3;LIN28;MOV10;NOP56;NOP58;PRPF8;SRSF1;TAF15;TARDBP;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-
GBMEERIRENSG00000089060.7chr12113318963:113320686:113320849:113320878-0.35824.2275e-031.3942e-06-0.4240imageNCNBP;CPSF6;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LIN28;LIN28B;LSM11;NOP56;NOP58;PRPF8;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-
GBMEERIRENSG00000124074.7chr1667663936:67664062:67664995:67665168-0.43225.9254e-042.2204e-07-0.4252imageNCNBP;CPSF6;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28B;LSM11;MOV10;NOP56;NOP58;PRPF8;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TRA2A;TROVE2;U2AF2;UPF1;XRN2;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-
GBMEERIRENSG00000146576.8chr76607505:6607597:6607959:6608070-0.35994.2967e-033.3651e-07-0.4407imageNCNBP;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LIN28;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PRPF8;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NANK_cells_restingGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-
GBMEERIRENSG00000147133.11chrX71423116:71423239:71423973:71424066-0.39373.7890e-046.0413e-07-0.4528imageNCNBP;CPSF6;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LIN28;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PRPF8;PUM2;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
chr19:52616712-52618719:-
GBMEERIRENSG00000159214.8chr143991607:43992639:43993889:43993964-0.37631.3768e-032.3389e-06-0.4206imageNCPSF6;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;PRPF8;SAFB2;SLTM;SRSF1;SRSF9;TAF15;U2AF2;UPF1;XRN2NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-
GBMEERIRENSG00000165819.7chr1421498132:21499371:21499491:21499600-0.37328.9969e-035.9436e-07-0.4099imageNCNBP;CPSF6;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LIN28;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PRPF8;PUM2;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:52616712-52618719:-
GBMEERIRENSG00000135597.14chr6138915857:138917624:138920214:138920316-0.38073.7933e-046.6133e-06-0.4220imageNCNBP;CPSF6;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FXR1;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LIN28;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PRPF8;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF2;UPF1;XRN2;ZNF184NANeutrophilsGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results



Top

5. Enriched editing regions and immune infiltration for ZNF83


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:52616712-52618719:-ACCEEREosinophils5.6609e-040.4321image
ENSG00000167766.17,ZNF83ACCEAGEosinophils1.8774e-040.4504image
chr19:52616712-52618719:-BLCAEERMacrophages_M28.3174e-03-0.1676image
chr19:52639153-52639740:-BLCAEERMonocytes3.5526e-020.2270image
ENSG00000167766.17,ZNF83BLCAEAGT_cells_CD4_naive2.6912e-02-0.1183image
chr19:52603667-52613324:-BRCAEERDendritic_cells_resting3.6175e-020.2457image
chr19:52616712-52618719:-BRCAEERB_cells_naive1.0880e-02-0.0863image
chr19:52639153-52639740:-BRCAEERMast_cells_resting1.1980e-02-0.1912image
chr19:52641569-52647604:-BRCAEERT_cells_CD4_naive4.4861e-020.0653image
ENSG00000167766.17,ZNF83BRCAEAGB_cells_naive3.2089e-02-0.0668image
chr19:52616712-52618719:-CESCEERDendritic_cells_resting1.0688e-020.1942image
chr19:52641569-52647604:-CESCEERDendritic_cells_activated1.7866e-020.1571image
ENSG00000167766.17,ZNF83CESCEAGDendritic_cells_activated3.9483e-030.1810image
chr19:52641569-52647604:-CHOLEERMacrophages_M11.0161e-020.5358image
ENSG00000167766.17,ZNF83CHOLEAGMacrophages_M15.3636e-030.5035image
chr19:52639153-52639740:-COADEERT_cells_CD4_naive2.2731e-020.4943image
chr19:52641569-52647604:-COADEEREosinophils7.4454e-030.3173image
ENSG00000167766.17,ZNF83COADEAGT_cells_regulatory_(Tregs)2.8291e-020.1663image
chr19:52641569-52647604:-DLBCEERT_cells_CD81.5325e-020.4316image
ENSG00000167766.17,ZNF83DLBCEAGT_cells_gamma_delta3.8991e-02-0.3505image
chr19:52616712-52618719:-ESCAEERMacrophages_M23.9350e-020.1950image
chr19:52635479-52636980:-ESCAEERT_cells_CD4_memory_resting8.6767e-03-0.4431image
chr19:52641569-52647604:-ESCAEERPlasma_cells1.1698e-020.2375image
ENSG00000167766.17,ZNF83ESCAEAGNeutrophils2.3904e-02-0.1988image
chr19:52641569-52647604:-GBMEERDendritic_cells_resting2.5992e-020.2624image
chr19:52616712-52618719:-HNSCEERT_cells_CD4_memory_activated3.1488e-020.2574image
chr19:52641569-52647604:-HNSCEERMast_cells_resting1.0645e-02-0.1894image
ENSG00000167766.17,ZNF83HNSCEAGMast_cells_resting4.9642e-03-0.2015image
chr19:52616712-52618719:-KICHEERB_cells_naive1.0025e-02-0.3444image
ENSG00000167766.17,ZNF83KICHEAGB_cells_naive1.7306e-02-0.3170image
chr19:52603667-52613324:-KIRCEERT_cells_CD4_memory_resting1.7875e-02-0.2886image
chr19:52616712-52618719:-KIRCEERMacrophages_M22.2686e-02-0.1260image
chr19:52639153-52639740:-KIRCEERMast_cells_activated1.7540e-020.2984image
ENSG00000167766.17,ZNF83KIRCEAGMacrophages_M22.8316e-02-0.1184image
chr19:52616712-52618719:-KIRPEERMacrophages_M11.8342e-030.2035image
chr19:52639153-52639740:-KIRPEERB_cells_naive3.8121e-030.2689image
chr19:52641569-52647604:-KIRPEERT_cells_CD4_memory_activated1.1268e-020.1714image
ENSG00000167766.17,ZNF83KIRPEAGMacrophages_M13.2329e-030.1827image
chr19:52616712-52618719:-LAMLEERT_cells_CD4_memory_activated4.8251e-020.1655image
chr19:52641569-52647604:-LAMLEERB_cells_naive3.7489e-020.1748image
chr19:52616712-52618719:-LIHCEEREosinophils6.5764e-040.3846image
chr19:52641569-52647604:-LIHCEERDendritic_cells_activated7.8048e-030.3090image
ENSG00000167766.17,ZNF83LIHCEAGMast_cells_resting2.4735e-020.2131image
chr19:52616712-52618719:-LUADEEREosinophils8.6017e-03-0.1438image
chr19:52641569-52647604:-LUADEERT_cells_regulatory_(Tregs)2.5961e-02-0.1450image
chr19:52641569-52647604:-LUSCEERT_cells_follicular_helper5.4976e-030.1986image
chr19:52616712-52618719:-MESOEERT_cells_gamma_delta8.8983e-040.4512image
chr19:52641569-52647604:-MESOEERDendritic_cells_activated1.9785e-040.6288image
ENSG00000167766.17,ZNF83MESOEAGT_cells_follicular_helper1.6759e-020.3130image
chr19:52616712-52618719:-OVEERDendritic_cells_resting1.1489e-030.2086image
chr19:52635479-52636980:-OVEERNK_cells_activated2.4070e-02-0.2657image
chr19:52639153-52639740:-OVEERMast_cells_resting1.2743e-050.3355image
ENSG00000167766.17,ZNF83OVEAGT_cells_CD83.9329e-020.1226image
chr19:52616712-52618719:-PAADEERMacrophages_M11.7498e-02-0.2006image
ENSG00000167766.17,ZNF83PAADEAGEosinophils2.5964e-020.1806image
ENSG00000167766.17,ZNF83PCPGEAGT_cells_gamma_delta3.8043e-02-0.1684image
chr19:52616712-52618719:-PRADEERNK_cells_activated1.3486e-020.1303image
ENSG00000167766.17,ZNF83PRADEAGT_cells_regulatory_(Tregs)1.6432e-02-0.1180image
chr19:52641569-52647604:-READEERT_cells_regulatory_(Tregs)6.3242e-03-0.5034image
ENSG00000167766.17,ZNF83READEAGDendritic_cells_activated2.6420e-02-0.2673image
chr19:52616712-52618719:-SARCEERDendritic_cells_activated6.6937e-040.3014image
chr19:52641569-52647604:-SARCEERMacrophages_M13.4215e-02-0.1665image
ENSG00000167766.17,ZNF83SARCEAGPlasma_cells5.2235e-040.2506image
chr19:52616712-52618719:-SKCMEERMonocytes4.2951e-02-0.1385image
chr19:52641569-52647604:-SKCMEERT_cells_CD4_memory_activated4.0112e-03-0.2016image
ENSG00000167766.17,ZNF83SKCMEAGT_cells_CD4_memory_activated3.5712e-02-0.1260image
chr19:52603667-52613324:-STADEERT_cells_CD4_memory_activated1.3249e-020.1961image
chr19:52616712-52618719:-STADEERB_cells_naive1.5337e-02-0.1541image
chr19:52635479-52636980:-STADEEREosinophils1.6769e-03-0.3639image
chr19:52639153-52639740:-STADEERMacrophages_M11.3625e-02-0.1900image
ENSG00000167766.17,ZNF83STADEAGMacrophages_M04.6787e-020.1116image
chr19:52616712-52618719:-TGCTEERDendritic_cells_activated1.0458e-050.4556image
chr19:52641569-52647604:-TGCTEERMonocytes1.1370e-020.2041image
ENSG00000167766.17,ZNF83TGCTEAGMonocytes1.4415e-030.2538image
chr19:52616712-52618719:-THCAEERT_cells_CD4_naive1.2288e-02-0.1215image
chr19:52641569-52647604:-THCAEERB_cells_memory1.2540e-02-0.1609image
ENSG00000167766.17,ZNF83THCAEAGT_cells_CD4_naive2.8525e-02-0.1027image
chr19:52616712-52618719:-THYMEEREosinophils3.6792e-020.2637image
chr19:52639153-52639740:-THYMEERB_cells_naive8.6484e-030.5455image
ENSG00000167766.17,ZNF83THYMEAGB_cells_naive2.3335e-030.2913image
chr19:52616712-52618719:-UCECEERPlasma_cells1.9698e-020.2587image
chr19:52616712-52618719:-UCSEERDendritic_cells_resting2.3604e-020.4603image
chr19:52641569-52647604:-UCSEERT_cells_CD82.3232e-02-0.3496image
ENSG00000167766.17,ZNF83UCSEAGMacrophages_M22.1978e-020.3300image
chr19:52616712-52618719:-UVMEERT_cells_CD4_memory_activated4.7341e-020.4272image


Top

6. Enriched editing regions and immune gene sets for ZNF83


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr19:52616712-52618719:-BRCAEER4.3502e-040.11903.8928e-030.09783.3206e-030.09941.5191e-050.1461image
chr19:52641569-52647604:-KIRCEER1.7524e-020.14904.0386e-020.12872.7028e-020.13884.3371e-020.1269image
chr19:52616712-52618719:-STADEER5.0643e-040.21971.0414e-020.16271.4605e-030.20141.7766e-040.2363image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:52616712-52618719:-ACCGSVA_HALLMARK_MYC_TARGETS_V1EER1.6828e-020.3076image
ENSG00000167766.17,ZNF83ACCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.6246e-030.3699image
chr19:52616712-52618719:-BLCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER3.1750e-020.1367image
ENSG00000167766.17,ZNF83BLCAGSVA_HALLMARK_P53_PATHWAYEAG9.9178e-050.2066image
chr19:52639153-52639740:-BLCAGSVA_HALLMARK_MYC_TARGETS_V1EER2.5447e-040.3848image
chr19:52641569-52647604:-BLCAGSVA_HALLMARK_P53_PATHWAYEER5.8073e-040.1978image
chr19:52641569-52647604:-BRCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER7.1164e-120.2205image
chr19:52603667-52613324:-BRCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.8142e-040.4246image
chr19:52616712-52618719:-BRCAGSVA_HALLMARK_UV_RESPONSE_UPEER4.7058e-060.1545image
chr19:52639153-52639740:-BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEER3.7028e-040.2684image
ENSG00000167766.17,ZNF83BRCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.0096e-130.2292image
chr19:52641569-52647604:-CESCGSVA_HALLMARK_MTORC1_SIGNALINGEER2.9621e-020.1444image
chr19:52616712-52618719:-CESCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.1623e-020.1751image
ENSG00000167766.17,ZNF83CESCGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.5543e-040.2232image
chr19:52641569-52647604:-CHOLGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.3747e-02-0.4801image
chr19:52616712-52618719:-CHOLGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER2.6436e-020.4267image
chr19:52616712-52618719:-COADGSVA_HALLMARK_GLYCOLYSISEER2.3028e-020.1758image
chr19:52641569-52647604:-COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.0115e-02-0.2773image
ENSG00000167766.17,ZNF83COADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.7066e-020.1508image
ENSG00000167766.17,ZNF83DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.5240e-020.3570image
ENSG00000167766.17,ZNF83ESCAGSVA_HALLMARK_MYOGENESISEAG9.6394e-050.3365image
chr19:52639153-52639740:-ESCAGSVA_HALLMARK_SPERMATOGENESISEER1.8982e-020.2651image
chr19:52616712-52618719:-ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER4.7248e-030.2651image
chr19:52641569-52647604:-ESCAGSVA_HALLMARK_MYOGENESISEER6.5862e-030.2553image
chr19:52635479-52636980:-ESCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER5.1000e-030.4694image
chr19:52603667-52613324:-ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEER2.3503e-02-0.2725image
ENSG00000167766.17,ZNF83GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.4189e-030.2653image
chr19:52616712-52618719:-GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.3885e-040.3187image
chr19:52641569-52647604:-GBMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER5.2533e-030.3256image
chr19:52616712-52618719:-HNSCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.2170e-020.2564image
chr19:52616712-52618719:-KICHGSVA_HALLMARK_SPERMATOGENESISEER2.1842e-020.3087image
ENSG00000167766.17,ZNF83KICHGSVA_HALLMARK_SPERMATOGENESISEAG9.8821e-030.3420image
chr19:52635479-52636980:-KIRCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER2.6157e-02-0.3144image
chr19:52616712-52618719:-KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.9155e-110.3600image
chr19:52603667-52613324:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.7628e-020.2892image
chr19:52641569-52647604:-KIRCGSVA_HALLMARK_PEROXISOMEEER9.0646e-050.2431image
chr19:52639153-52639740:-KIRCGSVA_HALLMARK_G2M_CHECKPOINTEER4.8520e-020.2496image
ENSG00000167766.17,ZNF83KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.1224e-110.3513image
chr19:52616712-52618719:-KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.9564e-050.2706image
chr19:52641569-52647604:-KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.2874e-030.2166image
ENSG00000167766.17,ZNF83KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.1858e-080.3456image
chr19:52639153-52639740:-KIRPGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.8356e-060.4225image
ENSG00000167766.17,ZNF83LAMLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.1476e-020.2066image
chr19:52641569-52647604:-LAMLGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.9528e-020.1958image
chr19:52616712-52618719:-LGGGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.2968e-030.1460image
ENSG00000167766.17,ZNF83LGGGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.6689e-030.1491image
chr19:52616712-52618719:-LIHCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.2273e-020.2878image
chr19:52641569-52647604:-LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.3785e-020.2644image
ENSG00000167766.17,ZNF83LIHCGSVA_HALLMARK_PEROXISOMEEAG1.6265e-030.2957image
chr19:52616712-52618719:-LUADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.7817e-030.1543image
ENSG00000167766.17,ZNF83LUADGSVA_HALLMARK_COAGULATIONEAG1.9075e-030.1609image
chr19:52641569-52647604:-LUSCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER5.6822e-030.1979image
chr19:52616712-52618719:-LUSCGSVA_HALLMARK_MYC_TARGETS_V2EER1.7578e-020.1434image
chr19:52641569-52647604:-MESOGSVA_HALLMARK_APICAL_JUNCTIONEER3.6426e-02-0.3835image
chr19:52603667-52613324:-OVGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER1.5683e-02-0.2157image
ENSG00000167766.17,ZNF83OVGSVA_HALLMARK_DNA_REPAIREAG6.9650e-040.2004image
chr19:52641569-52647604:-OVGSVA_HALLMARK_DNA_REPAIREER9.5064e-040.1968image
chr19:52616712-52618719:-OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.4146e-020.1455image
ENSG00000167766.17,ZNF83PAADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.6688e-02-0.1798image
chr19:52641569-52647604:-PCPGGSVA_HALLMARK_PEROXISOMEEER3.0464e-02-0.2406image
ENSG00000167766.17,ZNF83PCPGGSVA_HALLMARK_DNA_REPAIREAG2.2822e-02-0.1846image
chr19:52616712-52618719:-PCPGGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.8164e-030.2520image
chr19:52616712-52618719:-PRADGSVA_HALLMARK_FATTY_ACID_METABOLISMEER3.3595e-030.1544image
chr19:52641569-52647604:-PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER6.3945e-030.2210image
ENSG00000167766.17,ZNF83PRADGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG4.4825e-040.1719image
chr19:52641569-52647604:-READGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.1544e-020.4071image
chr19:52641569-52647604:-SARCGSVA_HALLMARK_MITOTIC_SPINDLEEER5.1637e-04-0.2698image
chr19:52616712-52618719:-SARCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.9289e-020.2099image
chr19:52616712-52618719:-SKCMGSVA_HALLMARK_PEROXISOMEEER2.8192e-040.2458image
chr19:52641569-52647604:-SKCMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER2.2053e-020.1610image
ENSG00000167766.17,ZNF83SKCMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG8.3056e-050.2338image
chr19:52639153-52639740:-STADGSVA_HALLMARK_MYOGENESISEER5.2251e-050.3068image
chr19:52616712-52618719:-STADGSVA_HALLMARK_P53_PATHWAYEER3.7193e-060.2895image
ENSG00000167766.17,ZNF83STADGSVA_HALLMARK_GLYCOLYSISEAG1.3678e-060.2670image
chr19:52641569-52647604:-STADGSVA_HALLMARK_ANGIOGENESISEER5.5305e-070.2857image
chr19:52603667-52613324:-STADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER3.1526e-030.2328image
chr19:52616712-52618719:-TGCTGSVA_HALLMARK_FATTY_ACID_METABOLISMEER3.5096e-020.2276image
ENSG00000167766.17,ZNF83TGCTGSVA_HALLMARK_MYC_TARGETS_V2EAG1.1828e-08-0.4382image
chr19:52641569-52647604:-TGCTGSVA_HALLMARK_MYC_TARGETS_V2EER3.8529e-05-0.3263image
chr19:52616712-52618719:-THCAGSVA_HALLMARK_GLYCOLYSISEER6.7615e-050.1923image
chr19:52603667-52613324:-THCAGSVA_HALLMARK_HEME_METABOLISMEER1.8195e-020.3970image
ENSG00000167766.17,ZNF83THCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.5547e-030.1479image
chr19:52641569-52647604:-THCAGSVA_HALLMARK_MITOTIC_SPINDLEEER3.1480e-020.1389image
chr19:52616712-52618719:-THYMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.4694e-020.3061image
ENSG00000167766.17,ZNF83THYMGSVA_HALLMARK_P53_PATHWAYEAG3.9503e-030.2764image
chr19:52641569-52647604:-UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.0795e-030.2467image
ENSG00000167766.17,ZNF83UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.5938e-030.2374image
chr19:52616712-52618719:-UCECGSVA_HALLMARK_MYOGENESISEER1.1641e-020.2791image
chr19:52639153-52639740:-UCECGSVA_HALLMARK_APICAL_SURFACEEER7.3318e-040.5584image
chr19:52616712-52618719:-UCSGSVA_HALLMARK_UV_RESPONSE_DNEER3.0714e-030.5784image
chr19:52641569-52647604:-UCSGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER5.0923e-030.4244image
ENSG00000167766.17,ZNF83UCSGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.0705e-020.3331image


Top

7. Enriched editing regions and drugs for ZNF83


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:52616712-52618719:-ACCAZD6482EER1.4221e-020.3150image
chr19:52641569-52647604:-ACCFH535EER5.7540e-03-0.4999image
chr19:52616712-52618719:-BLCAA.443654EER1.6646e-04-0.2373image
ENSG00000167766.17,ZNF83BLCAABT.263EAG6.7870e-040.1808image
chr19:52639153-52639740:-BLCACCT007093EER2.4602e-030.3225image
chr19:52641569-52647604:-BLCAABT.263EER7.2266e-050.2274image
chr19:52641569-52647604:-BRCAGSK269962AEER8.4511e-07-0.1597image
chr19:52616712-52618719:-BRCAATRAEER3.7319e-020.0707image
ENSG00000167766.17,ZNF83BRCAABT.263EAG7.2314e-050.1236image
chr19:52639153-52639740:-BRCAEtoposideEER3.7651e-040.2681image
chr19:52603667-52613324:-BRCAGefitinibEER3.5171e-020.2470image
ENSG00000167766.17,ZNF83CESCGW843682XEAG8.5596e-030.1653image
chr19:52641569-52647604:-CESCDocetaxelEER9.2871e-03-0.1723image
chr19:52616712-52618719:-CESCABT.888EER3.8526e-030.2193image
chr19:52616712-52618719:-CHOLBAY.61.3606EER1.8102e-040.6598image
ENSG00000167766.17,ZNF83CHOLDMOGEAG1.1377e-03-0.5738image
chr19:52641569-52647604:-COADCGP.60474EER9.4487e-040.3867image
chr19:52616712-52618719:-COADCGP.082996EER1.0256e-020.1982image
ENSG00000167766.17,ZNF83COADCGP.082996EAG6.6929e-040.2554image
chr19:52641569-52647604:-DLBCAUY922EER2.4276e-02-0.4038image
ENSG00000167766.17,ZNF83ESCABexaroteneEAG7.3001e-06-0.3834image
chr19:52639153-52639740:-ESCABicalutamideEER3.4566e-02-0.2397image
chr19:52635479-52636980:-ESCAJNK.Inhibitor.VIIIEER8.8430e-03-0.4421image
chr19:52603667-52613324:-ESCACEP.701EER1.3548e-05-0.4977image
chr19:52616712-52618719:-ESCAGSK269962AEER3.0285e-04-0.3352image
chr19:52641569-52647604:-ESCABexaroteneEER1.7281e-03-0.2928image
chr19:52616712-52618719:-GBMLenalidomideEER2.3401e-030.2570image
ENSG00000167766.17,ZNF83GBMLenalidomideEAG2.8855e-030.2483image
ENSG00000167766.17,ZNF83HNSCAMG.706EAG3.4513e-02-0.1523image
chr19:52641569-52647604:-HNSCATRAEER2.1476e-030.2267image
ENSG00000167766.17,ZNF83KICHBortezomibEAG4.2015e-030.3768image
chr19:52616712-52618719:-KICHLapatinibEER6.9508e-030.3599image
ENSG00000167766.17,ZNF83KIRCLapatinibEAG4.1656e-05-0.2194image
chr19:52641569-52647604:-KIRCCGP.082996EER1.2603e-04-0.2383image
chr19:52616712-52618719:-KIRCBIRB.0796EER2.8935e-040.1992image
chr19:52635479-52636980:-KIRCAZD8055EER1.3358e-030.4413image
chr19:52603667-52613324:-KIRCCGP.082996EER2.5752e-02-0.2724image
chr19:52641569-52647604:-KIRPDoxorubicinEER1.5117e-040.2539image
chr19:52616712-52618719:-KIRPGSK.650394EER1.8853e-030.2030image
chr19:52639153-52639740:-KIRPAZD6244EER2.5407e-040.3363image
ENSG00000167766.17,ZNF83KIRPCCT018159EAG7.2275e-070.3027image
chr19:52616712-52618719:-LAMLBleomycinEER1.1460e-03-0.2693image
chr19:52641569-52647604:-LAMLBicalutamideEER7.8255e-03-0.2224image
ENSG00000167766.17,ZNF83LAMLCHIR.99021EAG9.6532e-04-0.2677image
chr19:52616712-52618719:-LGGEmbelinEER1.8529e-040.1785image
chr19:52641569-52647604:-LGGAP.24534EER4.0872e-020.2903image
ENSG00000167766.17,ZNF83LGGBryostatin.1EAG2.2929e-040.1744image
ENSG00000167766.17,ZNF83LIHCErlotinibEAG1.9061e-02-0.2353image
chr19:52616712-52618719:-LIHCMidostaurinEER1.5765e-030.3587image
chr19:52641569-52647604:-LIHCBryostatin.1EER5.5804e-03-0.3213image
chr19:52616712-52618719:-LUADATRAEER4.1425e-030.1567image
ENSG00000167766.17,ZNF83LUADABT.263EAG8.8516e-030.1363image
chr19:52641569-52647604:-LUADGDC0941EER3.4240e-02-0.1379image
ENSG00000167766.17,ZNF83LUSCCCT018159EAG1.1743e-020.1427image
chr19:52641569-52647604:-LUSCGW.441756EER1.9223e-03-0.2214image
chr19:52616712-52618719:-LUSCCGP.60474EER4.2308e-020.1228image
ENSG00000167766.17,ZNF83MESOAMG.706EAG1.2869e-020.3248image
chr19:52616712-52618719:-MESOCEP.701EER6.5383e-03-0.3760image
chr19:52641569-52647604:-MESOBI.2536EER3.1713e-030.5208image
chr19:52641569-52647604:-OVMG.132EER9.9035e-05-0.2313image
chr19:52616712-52618719:-OVAUY922EER7.3042e-030.1728image
chr19:52639153-52639740:-OVABT.263EER3.8168e-040.2758image
chr19:52635479-52636980:-OVDMOGEER3.7895e-02-0.2452image
chr19:52603667-52613324:-OVBMS.536924EER3.2357e-03-0.2614image
ENSG00000167766.17,ZNF83OVMG.132EAG4.4424e-04-0.2078image
ENSG00000167766.17,ZNF83PAADBIRB.0796EAG4.5260e-04-0.2810image
chr19:52641569-52647604:-PAADCisplatinEER2.6844e-040.3351image
chr19:52616712-52618719:-PAADBleomycinEER4.4115e-040.2931image
chr19:52641569-52647604:-PCPGABT.888EER1.7753e-03-0.3420image
chr19:52616712-52618719:-PCPGBMS.708163EER6.9939e-03-0.2355image
ENSG00000167766.17,ZNF83PCPGKIN001.135EAG2.8437e-02-0.1778image
ENSG00000167766.17,ZNF83PRADCMKEAG3.9380e-040.1736image
chr19:52641569-52647604:-PRADBMS.754807EER4.1504e-02-0.1661image
chr19:52616712-52618719:-PRADEHT.1864EER2.7435e-05-0.2194image
chr19:52641569-52647604:-READAZD6244EER1.4755e-020.4559image
ENSG00000167766.17,ZNF83READAZD6244EAG3.7657e-020.2508image
ENSG00000167766.17,ZNF83SARCKIN001.135EAG5.2266e-030.2029image
chr19:52616712-52618719:-SARCCyclopamineEER1.1295e-02-0.2268image
chr19:52641569-52647604:-SARCBleomycinEER1.0422e-04-0.3002image
chr19:52616712-52618719:-SKCMGW843682XEER3.9472e-02-0.1409image
chr19:52641569-52647604:-SKCMGefitinibEER3.0916e-030.2077image
ENSG00000167766.17,ZNF83SKCMBexaroteneEAG2.3381e-03-0.1818image
chr19:52641569-52647604:-STADAZ628EER1.8497e-04-0.2153image
ENSG00000167766.17,ZNF83STADAZ628EAG1.3713e-03-0.1787image
chr19:52616712-52618719:-STADCCT007093EER1.7568e-040.2365image
chr19:52639153-52639740:-STADAZ628EER2.4795e-03-0.2320image
chr19:52635479-52636980:-STADAMG.706EER2.8848e-02-0.2577image
chr19:52603667-52613324:-STADBMS.509744EER3.0510e-03-0.2335image
chr19:52641569-52647604:-TGCTLFM.A13EER7.2044e-07-0.3880image
chr19:52616712-52618719:-TGCTCytarabineEER1.2778e-02-0.2675image
ENSG00000167766.17,ZNF83TGCTLFM.A13EAG5.9585e-09-0.4461image
chr19:52616712-52618719:-THCAEtoposideEER5.7332e-040.1666image
chr19:52603667-52613324:-THCAAZD.2281EER2.9017e-020.3693image
ENSG00000167766.17,ZNF83THCAErlotinibEAG1.1161e-040.1802image
chr19:52641569-52647604:-THCABX.795EER4.2240e-020.1312image
chr19:52641569-52647604:-THYMBIBW2992EER9.2239e-03-0.2686image
chr19:52616712-52618719:-THYMEmbelinEER1.2339e-030.3981image
ENSG00000167766.17,ZNF83THYMCMKEAG2.2077e-030.2928image
ENSG00000167766.17,ZNF83UCECAZD7762EAG1.6808e-02-0.2011image
chr19:52616712-52618719:-UCECAKT.inhibitor.VIIIEER2.0835e-040.4009image
chr19:52641569-52647604:-UCECAZD7762EER1.1064e-02-0.2331image
chr19:52639153-52639740:-UCECAZD7762EER2.6458e-03-0.5063image
chr19:52616712-52618719:-UCSCCT018159EER2.4192e-020.4586image
chr19:52641569-52647604:-UCSMG.132EER4.2045e-03-0.4328image
ENSG00000167766.17,ZNF83UCSAKT.inhibitor.VIIIEAG9.7872e-03-0.3693image
chr19:52616712-52618719:-UVMGW.441756EER2.5906e-040.7036image
ENSG00000167766.17,ZNF83UVMGDC.0449EAG4.1573e-030.5528image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType